Primary Objective:
To characterize the patients who receive Dupixent (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD
Secondary Objectives:
Participants enrolled in the study will be followed for 5 years.
Treatment | Dupilumab SAR231893 (REGN668) |
---|---|
Clinical Study Identifier | NCT03992417 |
Sponsor | Sanofi |
Last Modified on | 5 October 2020 |
Select a piece of text and start making personal notes.
,
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerCongrats! You have your own personal workspace now.